Small Pharma works on the development of two drugs. Together with Imperial College London, they are developing intravenous administration DMT. The other project is a variant on ketamine (SPL801B).
“Many valuable drug development opportunities, either from academia or from discovery-focused biotech companies, lose their way in development and never reach the patients who should benefit from them. Small Pharma is dedicated to identifying these opportunities and ensuring that the value in the underlying pharmaceutical assets is preserved.”
In April 2021, Small Pharma completed a broker led subscription receipt financing of $45 million and a non-brokered convertible note financing of $4 million.
The company are listed TSXV (Canadian) stock exchange under the ticker DMT.
Peter Rands – CEO
- Psychedelic drug DMT to be trialled in UK to treat depression (The Guardian, December 2020)
- UK government set for psychedelics investment windfall (Financial Times, December 2020)
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates